Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pacific Edge Limited ( (NZ:PEB) ) has issued an announcement.
Pacific Edge Limited has opened a NZ$6 million retail share offer to eligible New Zealand shareholders, following a NZ$25.4 million institutional placement at NZ$0.17 per share. Investors can apply for up to NZ$50,000 of new shares at the same price as the placement, with the offer closing on 28 May 2026 and the new shares ranking equally with existing stock on the NZX.
The combined placement and retail offer are designed to strengthen the company’s balance sheet to support ongoing operations and growth, secure Medicare re-coverage, and fund further evidence generation, product development and innovation. Management says the capital raise will help consolidate Pacific Edge’s position in bladder cancer diagnostics and back its push for broader test adoption in the U.S. and Asia-Pacific markets.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specialising in bladder cancer diagnostic and prognostic tests for patients with hematuria or recurrent disease. Headquartered in Dunedin, New Zealand, it markets its non-invasive Cxbladder genomic urine tests through CLIA-certified laboratories in New Zealand and the U.S., with availability across the U.S., Australasia, Israel, Asia and South America.
Average Trading Volume: 531,948
Technical Sentiment Signal: Hold
Current Market Cap: N$177.9M
For a thorough assessment of PEB stock, go to TipRanks’ Stock Analysis page.